A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study
Titel:
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study
Auteur:
Reyners, A.K.L. de Munck, L. Erdkamp, F.L.G. Smit, W.M. Hoekman, K. Lalisang, R.I. de Graaf, H. Wymenga, A.N.M. Polee, M. Hollema, H. van Vugt, M.A.T.M. Schaapveld, M. Willemse, P.H.B.